Class Action Firm Recognition: Monteverde & Associates PC, led by attorney Juan Monteverde, is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has successfully recovered millions for shareholders.
PB Bankshares Investigation: The firm is investigating PB Bankshares Inc. regarding its sale to Norwood Financial Corp., where shareholders can choose between shares or cash, with a shareholder vote scheduled for December 10, 2025.
Other Mergers and Acquisitions: The firm is also involved in cases related to Voyager Acquisition Corp.'s merger with Veraxa Biotech AG, Lifeloc Technologies' merger with Electronic Systems Technology, and Semler Scientific's sale to Strive, Inc.
Contact Information: Shareholders with concerns or seeking more information can contact Juan Monteverde via email or phone, with services offered at no cost or obligation.
Wall Street analysts forecast SMLR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SMLR is 68.50 USD with a low forecast of 51.00 USD and a high forecast of 86.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast SMLR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SMLR is 68.50 USD with a low forecast of 51.00 USD and a high forecast of 86.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 20.340
Low
51.00
Averages
68.50
High
86.00
Current: 20.340
Low
51.00
Averages
68.50
High
86.00
Maxim
Matthew Galinko
Buy
downgrade
$95 -> $80
Al Analysis
2025-09-19
Reason
Maxim
Matthew Galinko
Price Target
$95 -> $80
Al Analysis
2025-09-19
downgrade
Buy
Reason
Maxim analyst Matthew Galinko lowered the firm's price target on Semler Scientific to $80 from $95 and keeps a Buy rating on the shares. The firm is cutting its estimates for revenue in 2025-27 due to the management's guidance and its own estimates, the analyst tells investors in a research note. Maxim also cites Semler having entered into a settlement agreement with the Civil Fraud Section of the Department of Justice, the Department of Health and Human Services, and certain relators to settle all potential claims related to alleged civil violations of the False Claims Act, the firm added.
Cantor Fitzgerald
Brett Knoblauch
initiated
$61
2025-07-28
Reason
Cantor Fitzgerald
Brett Knoblauch
Price Target
$61
2025-07-28
initiated
Reason
Cantor Fitzgerald analyst Brett Knoblauch initiated coverage of Semler Scientific with an Overweight rating and $61 price target.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SMLR
Unlock Now
Maxim
NULL -> Buy
initiated
$95
2025-07-09
Reason
Maxim
Price Target
$95
2025-07-09
initiated
NULL -> Buy
Reason
Maxim initiated coverage of Semler Scientific with a Buy rating and $95 price target.
Lake Street
Brooks O'Neil
Strong Buy
Maintains
$40 → $71
2025-01-24
Reason
Lake Street
Brooks O'Neil
Price Target
$40 → $71
2025-01-24
Maintains
Strong Buy
Reason
About SMLR
Semler Scientific, Inc. is engaged in developing and marketing technology products and services to healthcare providers to combat chronic diseases. The Company's flagship product, QuantaFlo, which is patented and cleared by the United States Food and Drug Administration (FDA), is a rapid point-of-care test that measures arterial blood flow in the extremities. The QuantaFlo test aids in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD), and the Company is seeking a new 510(k) clearance for expanded-indications. QuantaFlo is used by healthcare providers to evaluate their patient's risk of mortality and major adverse cardiovascular events (MACE). QuantaFlo features a sensor clamp that is placed on the toe or finger. A blood flow waveform is instantaneously constructed by its software algorithm. The Company delivers QuantaFlo directly to its customers. The Company also invests in bitcoin and has adopted Bitcoin as its primary treasury asset.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
